# Targeted Fluorescence Imaging in AMD

> **NCT05262244** · PHASE1 · COMPLETED · sponsor: **University Medical Center Groningen** · enrollment: 12 (actual)

## Conditions studied

- Age-Related Macular Degeneration
- NAMD

## Interventions

- **DRUG:** Bevacizumab-IRDye800CW

## Key facts

- **NCT ID:** NCT05262244
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-28
- **Primary completion:** 2023-03-30
- **Final completion:** 2024-03-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05262244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05262244, "Targeted Fluorescence Imaging in AMD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05262244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*